BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

744 related articles for article (PubMed ID: 29116596)

  • 1. Antibody-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments.
    Nagayama A; Ellisen LW; Chabner B; Bardia A
    Target Oncol; 2017 Dec; 12(6):719-739. PubMed ID: 29116596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review.
    Lambert JM; Morris CQ
    Adv Ther; 2017 May; 34(5):1015-1035. PubMed ID: 28361465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-Drug Conjugates for Cancer Treatment.
    Lambert JM; Berkenblit A
    Annu Rev Med; 2018 Jan; 69():191-207. PubMed ID: 29414262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-Drug Conjugates: A Clinical Pharmacy Perspective on an Emerging Cancer Therapy.
    Jerjian TV; Glode AE; Thompson LA; O'Bryant CL
    Pharmacotherapy; 2016 Jan; 36(1):99-116. PubMed ID: 26799352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-targeted drugs and drug resistance--challenges and solutions.
    Shefet-Carasso L; Benhar I
    Drug Resist Updat; 2015 Jan; 18():36-46. PubMed ID: 25476546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical perspective: Antibody-drug conjugates for the treatment of HER2-positive breast cancer.
    Najminejad Z; Dehghani F; Mirzaei Y; Mer AH; Saghi SA; Abdolvahab MH; Bagheri N; Meyfour A; Jafari A; Jahandideh S; Gharibi T; Amirkhani Z; Delam H; Mashatan N; Shahsavarani H; Abdollahpour-Alitappeh M
    Mol Ther; 2023 Jul; 31(7):1874-1903. PubMed ID: 36950736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody drug conjugates.
    Bakhtiar R
    Biotechnol Lett; 2016 Oct; 38(10):1655-64. PubMed ID: 27334710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody-drug conjugates for cancer.
    Chau CH; Steeg PS; Figg WD
    Lancet; 2019 Aug; 394(10200):793-804. PubMed ID: 31478503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates.
    Sun X; Ponte JF; Yoder NC; Laleau R; Coccia J; Lanieri L; Qiu Q; Wu R; Hong E; Bogalhas M; Wang L; Dong L; Setiady Y; Maloney EK; Ab O; Zhang X; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM
    Bioconjug Chem; 2017 May; 28(5):1371-1381. PubMed ID: 28388844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody-drug conjugates: A promising novel therapeutic approach in lung cancer.
    Desai A; Abdayem P; Adjei AA; Planchard D
    Lung Cancer; 2022 Jan; 163():96-106. PubMed ID: 34942494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting Response to Antibody Drug Conjugates: A Focus on Antigens' Targetability.
    Ascione L; Crimini E; Trapani D; Marra A; Criscitiello C; Curigliano G
    Oncologist; 2023 Nov; 28(11):944-960. PubMed ID: 37665782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody-Drug Conjugates in Gynecologic Cancer.
    Karpel HC; Powell SS; Pothuri B
    Am Soc Clin Oncol Educ Book; 2023 May; 43():e390772. PubMed ID: 37229642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985).
    Xu Z; Guo D; Jiang Z; Tong R; Jiang P; Bai L; Chen L; Zhu Y; Guo C; Shi J; Yu D
    Eur J Med Chem; 2019 Dec; 183():111682. PubMed ID: 31563805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent Advances in Antibody-Drug Conjugates for Breast Cancer Treatment.
    Deng S; Lin Z; Li W
    Curr Med Chem; 2017; 24(23):2505-2527. PubMed ID: 28554322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-Drug Conjugates for Breast Cancer.
    Marmé F
    Oncol Res Treat; 2022; 45(1-2):26-36. PubMed ID: 34915488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody-Drug Conjugates: The New Frontier of Chemotherapy.
    Ponziani S; Di Vittorio G; Pitari G; Cimini AM; Ardini M; Gentile R; Iacobelli S; Sala G; Capone E; Flavell DJ; Ippoliti R; Giansanti F
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32752132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody-drug conjugates: Promising and efficient tools for targeted cancer therapy.
    Nasiri H; Valedkarimi Z; Aghebati-Maleki L; Majidi J
    J Cell Physiol; 2018 Sep; 233(9):6441-6457. PubMed ID: 29319167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy.
    Goldenberg DM; Sharkey RM
    Expert Opin Biol Ther; 2020 Aug; 20(8):871-885. PubMed ID: 32301634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-Drug Conjugates for Cancer Therapy.
    Hafeez U; Parakh S; Gan HK; Scott AM
    Molecules; 2020 Oct; 25(20):. PubMed ID: 33081383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody-drug conjugates: present and future.
    Beck A; Reichert JM
    MAbs; 2014; 6(1):15-7. PubMed ID: 24423577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.